Poly(oxy-1,2-ethanediyl), .alpha.,.alpha.'-[(1-methylethylidene)di-4,1-phenylene]bis[.omega.-hydroxy-, mixed acrylates and isononanoates

Endpoint summary

Description of key information

The potential of acute toxicity of 4,4'-lsopropylidenediphenol, ethoxylated, esters with acrylic acid and isononanoic acid was evaluated in two studies, one by oral route and one by dermal route. No mortalities were showed in both studies; the oral and dermal LD50 were higher than 2000 mg/kg in rats. 

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

15 April 2013 -- 03 July 2013

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Limit test:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: approximately 8 weeks old on the day of treatment
- Mean body weight at study initiation: 200 g (range: 190 g to 210 g)
- Fasting period before study: yes, during the night before treatment
- Housing: polycarbonate cages
- Diet: SSNIFF R/M-H pelleted diet (free access)
- Water: tap water filtered with a 0.22 µm filter (free access)
- Acclimation period: at least 5 days before the beginning of the study

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%
- Air changes (per hr): approximately 12 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12 h/12 h

IN-LIFE DATES: 21 May 2013 to 19 June 2013

Route of administration:

oral: gavage

Vehicle:

other: sesame oil

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 200 mg/mL
- Justification for choice of vehicle: as unsatisfactory solubility of the test item was obtained in drinking water treated by reverse osmosis (i.e. heterogeneous emulsion at the concentration of 200 mg/mL was obtained), another vehicle was chosen from the following organic solvents (in order of preference): 0.5% methylcellulose aqueous solution, corn oil, PEG 400 and sesame oil.
A homogenous emulsion was obtained at the concentration of 200 mg/mL in sesame oil.
- Maximum dose-volume applied: 10 mL/kg

CLASS METHOD:
- Rationale for the selection of the starting dose: since no relevant toxicity data were available for the estimation of a lethal dose-level and any existing data were taken into account by the Sponsor, the starting dose level was 300 mg/kg for ethical reasons.

Doses:

300 and 2000 mg/kg

No. of animals per sex per dose:

300 mg/kg: 3 females
2000 mg/kg : 3 females + 3 females

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Clinical observations: frequently during the hours following treatment; then, at least once a day.
- Body weight on the day of group allocation, just before treatment on day 1; then on days 8 and 15.
- Necropsy of survivors performed: yes (macroscopic).

Statistics:

no

Preliminary study:

no

Sex:

female

Dose descriptor:

LD0

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No unscheduled deaths occurred during the study.

Clinical signs:

other: At 2000 mg/kg, hunched posture was observed in 2/3 females from group 3 (B20327 and B20329) on days 1 and 2. This was associated with piloerection in one of these females (B20329) on day 1 only. No clinical signs were observed in any other animals.

Gross pathology:

There were no findings considered to be related to the test item administration.
Dilatation of the uterus with translucent content was noted in 2/3 females from group 1 given the test item at 300 mg/kg. This is a common background change in rats related to the estrous cycle.

Other findings:

no

 Table 1

Sex	Female
Group	historical control data	1	2	3
Dose-level (mg/kg)	0	300	2000	2000
Body weight (mean (± SD))
. Day 1	208 (± 11.7)	208 (± 2.5)	193 (± 2.6)	198 (± 6.1)
. Day 8	246 (± 12.7)	252 (± 3.2)	233 (± 11.6)	221 (± 3.1)
. Day 15	266 (± 14.0)	275 (± 13.1)	255 (± 7.4)	236 (± 2.5)
Body weight change (mean (± SD))
. Days 1-8	+39 (± 5.1)	+45 (± 2.1)	+40 (± 11.7)	+23 (± 6.0)
. Days 8-15	+20 (± 6.3)	+22 (± 10.8)	+21 (± 5.9)	+15 (± 3.1)
. Days 1-15	+58 (± 5.8)	+67 (± 10.5)	+62 (± 6.5)	+38 (± 8.1)

SD: standard deviations.

Interpretation of results:

GHS criteria not met

Conclusions:

Under the experimental conditions of this study, the oral LD50 of the test item, 4,4'-lsopropylidenediphenol, ethoxylated, esters with acrylic acid and isononanoic acid, was higher than 2000 mg/kg in rats.

Executive summary:

The objective of this study was to evaluate the potential acute toxicity of the test item following a single oral administration (gavage) to rats.

This study was conducted in compliance with OECD Guideline No. 423 and the principles of Good Laboratory Practices.

 

Methods

The test item was administered once by oral route (gavage) to three groups of three fasted female Sprague-Dawley rats under a dosage-volume of 10 mL/kg. The test item was prepared in sesame oil.

Since no relevant toxicity data were available for the estimation of a lethal dose-level and any existing data have been taken into account by the Sponsor, the starting dose-level was 300 mg/kg for ethical reasons. After the first assay, the next higher dose-level of 2000 mg/kg was tested. Then, as no toxicity was observed at this higher dose-level, the results were confirmed in other females.

Each animal was observed at least once a day for mortality and clinical signs for 15 days. Body weight was recorded on day 1 and then on days 8 and 15.

On completion of the observation period, the animals were sacrificed and then submitted for a macroscopic post-mortem examination.Macroscopic lesions were preservedin buffered formalinthendestroyed at the finalization of the study reportas no microscopic examination was performed.

Results

No unscheduled deaths occurred during the study.

At 2000 mg/kg, hunched posture was observed in 2/3 females from group 3 on days 1 and 2. This was associated with piloerection in one of these females on day 1 only. No clinical signs were observed in any other animals.

At 2000 mg/kg and when compared to historical control data, a lower body weight gain was noted in 2/3 females from group 3 over the whole study period. The body weight of the other animals was unaffected by the test item treatment.

The test item administration did not induce any macroscopic findings at necropsy.

Conclusion

Under the experimental conditions of this study, the oral LD50 of the test item was higher than 2000 mg/kg in rats.

Therefore, the test item should not be classified as harmful or toxic by oral route according to the criteria of CLP Regulation.

 

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Quality of whole database:

The oral acute study is considered to be a reliable study (klimisch score of 1).

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Study period:

15 April 2013 -- 10 July 2013

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: approximately 8 weeks old on the day of treatment
- Mean body weight at study initiation: the males had a mean body weight of 359 g (range: 345 g to 375 g) and the females had a mean body weight of 205 g (range: 199 g to 210 g).
- Fasting period before study: yes, during the night before treatment
- Housing: polycarbonate cages
- Diet: SSNIFF R/M-H pelleted diet (free access)
- Water: tap water filtered with a 0.22 µm filter (free access)
- Acclimation period: at least 5 days before the beginning of the study

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%
- Air changes (per hr): approximately 12 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12 h/12 h

IN-LIFE DATES: 11 June 2013 to 28 June 2013

Type of coverage:

semiocclusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

TEST SITE
- Area of exposure: 10% of body surface, dorsal site
- Type of wrap if used: hydrophilic gauze pad + adhesive hypoallergenic aerated semi-occlusive dressing + restraining bandage

REMOVAL OF TEST SUBSTANCE
- Removal of dressing: 24h post-exposure
- Washing: yes in females only

TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg
- Constant volume: no

Duration of exposure:

24 hours

Doses:

2000 mg/kg

No. of animals per sex per dose:

Ten rats (five males and five nulliparous and non pregnant females)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Clinical observations: frequently during the hours following treatment; then, at least once a day.
- Body weight on the day of group allocation, just before treatment on day 1; then on days 8 and 15.
- Necropsy of survivors performed: yes (macroscopic).

Statistics:

no

Preliminary study:

no

Sex:

male/female

Dose descriptor:

LD0

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

not determinable due to absence of adverse toxic effects

Mortality:

No unscheduled deaths occurred during the study.

Clinical signs:

other: No clinical signs indicative of systemic toxicity were observed in any animals. Four females presented with a very slight or a well-defined erythema from day 2 to day 6. Two animals from the four females had also a very slight to slight dryness of the ski

Gross pathology:

There were no macroscopic findings at necropsy.

Other findings:

no

Table 1

Sex	Female		Male
Group	historical control data	1	historical control data	2
Dose-level (mg/kg)	0	2000	0	2000
Body weight (mean (± SD))
. Day 1	236 (± 8.9)	205 (± 4.0)	362 (± 12.0)	359 (± 12.0)
. Day 8	253 (± 12.0)	229 (± 6.0)	394 (± 15.3)	384 (± 16.4)
. Day 15	273 (± 16.3)	248 (± 7.5)	441 (± 21.5)	420 (± 21.3)
Body weight change (mean (± SD))
. Days 1-8	+17 (± 11.0)	+24 (± 6.6)	+32 (± 9.1)	+25 (± 8.0)
. Days 8-15	+20 (± 7.1)	+19 (± 1.9)	+47 (± 7.5)	+36 (± 5.6)
. Days 1-15	+37 (± 16.3)	+43 (± 8.2)	+79 (± 15.6)	+61 (± 13.0)

SD: standard deviations.

 

Interpretation of results:

GHS criteria not met

Conclusions:

Under the experimental conditions of this study, the dermal LD50 of the test item was higher than 2000 mg/kg in rats.
Therefore, the test item should not be classified as acutely toxic by dermal route according to the criteria of CLP Regulation.

Executive summary:

The objective of this study was to evaluate the potential acute toxicity of the test item following a single dermal application to rats.

This study was conducted in compliance with OECD Guideline No. 402 and the principles of Good Laboratory Practices.

 

Methods

The test item was applied in its original form to the skin of five female then five male Sprague-Dawley rats at the dose-level of 2000 mg/kg. The application site was covered by a semi-occlusive dressing for 24 hours.

Each animal was observed at least once a day for mortality and clinical signs for 15 days. From day 2, any local reactions at the treatment site were also noted. Body weight was recorded on day 1 and then on days 8 and 15.

On completion of the observation period, the animals were sacrificed and then submitted to a macroscopic post-mortem examination. No tissues were preserved.

 

Results

No unscheduled deaths occurred during the study.

No clinical signs indicative of systemic toxicity were observed in any animals.

Four females presented with a very slight or a well-defined erythema from day 2 to day 6. Two animals from the four females had also a very slight to slight dryness of the skin and for one of them scabs almost during the same interval.

Although two females had similar findings before application of the test item (due to clipping), all these findings were considered to be due to the test item.

No cutaneous reactions were noted in any males.

In absence of marked body weight effect, an opposite tendency was noted in body weight gain (higher in females and lower in males in comparison with historical control data). This was considered not to be test item-related.

There were no macroscopic findings at necropsy.

 

Conclusion

Under the experimental conditions of this study, the dermal LD₅₀of the test item was higher than 2000 mg/kg in rats.

 

Therefore, the test item should not be classified as acutely toxic by dermal route according to the criteria of CLP Regulation.

 

 

 

 

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Quality of whole database:

The dermal acute study is considered to be a reliable study (klimisch score of 1).

Additional information

Acute toxicity: oral (Papineau 2013)

The objective of this study was to evaluate the potential acute toxicity of the test item following a single oral administration (gavage) to rats (OECD 423).

The test item was administered once by oral route (gavage) to three groups of three fasted female Sprague-Dawley rats under a dosage-volume of 10 mL/kg. The test item was prepared in sesame oil. Since no relevant toxicity data were available for the estimation of a lethal dose-level and any existing data have been taken into account by the Sponsor, the starting dose-level was 300 mg/kg for ethical reasons. After the first assay, the next higher dose-level of 2000 mg/kg was tested. Then, as no toxicity was observed at this higher dose-level, the results were confirmed in other females.

Each animal was observed at least once a day for mortality and clinical signs for 15 days. Body weight was recorded on day 1 and then on days 8 and 15.

No unscheduled deaths occurred during the study. At 2000 mg/kg, hunched posture was observed in 2/3 females from group 3 on days 1 and 2. This was associated with piloerection in one of these females on day 1 only. No clinical signs were observed in any other animals. At 2000 mg/kg and when compared to historical control data, a lower body weight gain was noted in 2/3 females from group 3 over the whole study period. The body weight of the other animals was unaffected by the test item treatment. The test item administration did not induce any macroscopic findings at necropsy.

Under the experimental conditions of this study, the oral LD50 of the test item was higher than 2000 mg/kg in rats.

Acute toxicity: dermal (Papineau 2013)

The objective of this study was to evaluate the potential acute toxicity of the test item following a single dermal application to rats (OECD 402)

The test itemwas applied in its original form to the skin of five female then five male Sprague-Dawley rats at the dose-level of 2000 mg/kg. The application site was covered by a semi-occlusive dressing for 24 hours. Each animal was observed at least once a day for mortality and clinical signs for 15 days. From day 2, any local reactions at the treatment site were also noted. Body weight was recorded on day 1 and then on days 8 and 15.

No unscheduled deaths occurred during the study. No clinical signs indicative of systemic toxicity were observed in any animals. Four females presented with a very slight or a well-defined erythema from day 2 to day 6. Two animals from the four females had also a very slight to slight dryness of the skin and for one of them scabs almost during the same interval. Although two females had similar findings before application of the test item (due to clipping), all these findings were considered to be due to the test item. No cutaneous reactions were noted in any males.

In absence of marked body weight effect, an opposite tendency was noted in body weight gain (higher in females and lower in males in comparison with historical control data). This was considered not to be test item-related. There were no macroscopic findings at necropsy.

Under the experimental conditions of this study, the dermal LD50 of the test item was higher than 2000 mg/kg in rats.

Justification for classification or non-classification

No mortality or severe clinical signs was observed in the acute toxicity studies performed at the limit dose, after oral and dermal exposure. Therefore 4,4'-lsopropylidenediphenol, ethoxylated, esters with acrylic acid and isononanoic acid is not classified for acute toxicity according to the Regulation EC 1272/2008.